Related Experiment Video
Updated: May 9, 2026
09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Noninvasive prenatal testing for trisomy 21: challenges for implementation in Australia.
1Department of Perinatal Medicine, Mercy Hospital for Women, Heidelberg, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia.
Summary
Non-invasive prenatal testing (NIPT) uses cell-free DNA to screen for Down syndrome and other chromosomal abnormalities. This review examines NIPT
Area of Science:
- Reproductive genetics
- Molecular diagnostics
- Prenatal screening
Background:
- Non-invasive prenatal testing (NIPT) is an emerging molecular technology.
- It analyzes cell-free DNA for prenatal screening.
- NIPT is available to Australian women via offshore laboratories.
Purpose of the Study:
- To review the basis of cell-free DNA testing.
- To evaluate the effectiveness of NIPT for trisomy 21 screening.
- To explore NIPT integration into current screening strategies.
Main Methods:
- Review of scientific literature on NIPT.
- Analysis of cell-free DNA assessment techniques.
- Examination of NIPT effectiveness data for trisomy 21.
Main Results:
- NIPT shows significant potential for screening chromosomal abnormalities.
- Effectiveness data for trisomy 21 screening is accumulating.
- Integration into existing strategies requires careful consideration.
Conclusions:
- NIPT represents a significant advancement in prenatal screening.
- Further research and strategic planning are needed for optimal implementation.
- NIPT offers a valuable tool for detecting fetal chromosomal abnormalities.
